Healthcare / Medical Instruments & SuppliesQatar
$1.43
-0.01 (-0.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.0M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$166M
P/E
15.9x
↓EV/EBITDA
19.8x
↑ROE
-39.6%
↓Gross Margin
33.9%
↓Debt/Equity
-6.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-52.5%
FCF CAGR
+18.3%
FCF margin
28.8%
FCF / Net income
0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.6M · net income $9.3M · FCF $1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.6M | $4.6M | $10.0M | $27.9M | $42.7M |
| Net Income | $9.3M | $9.3M | $-68.5M | $1.3M | $1.2M |
| EBITDA | $15.5M | $15.5M | $-53.0M | $9.4M | $10.5M |
| EPS | — | — | -0.59 | 0.01 | 0.01 |
| Gross Margin | 33.9% | 33.9% | 30.5% | 33.0% | 32.9% |
| Operating Margin | -166.7% | -166.7% | -600.8% | -3.4% | 6.4% |
| Net Margin | 202.8% | 202.8% | -685.9% | 4.8% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | -6.07 | -6.07 | -4.67 | 3.95 | 4.20 |
| Current Ratio | 0.85 | 0.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.3M | $1.3M | $1.0M | $-2.0M | $795748.00 |
| Returns | |||||
| ROE | -39.6% | -39.6% | 211.0% | 3.7% | 3.6% |
| Valuation | |||||
| P/E | 15.93 | 15.93 | — | 119.33 | 120.45 |
| EV/EBITDA | 19.83 | 19.83 | — | 32.76 | 27.87 |
| P/B | — | — | — | 4.59 | 4.44 |
| Growth & Yield | |||||
| Revenue Growth | -54.2% | -54.2% | -64.2% | -34.7% | — |
| EPS Growth | — | — | -5041.7% | 9.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.59 → n/d
Residual
-0.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.